Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs

Equality Impact Assessment (Guidance development) (PDF 251 KB)

Final appraisal determination

Final appraisal determination document (PDF 703 KB)

Public committee slides (PDF 413 KB)

Committee papers (PDF 1.89 MB)

Draft guidance: 2

Committee papers (PDF 2.13 MB)

Appraisal consultation document (PDF 568 KB)

Public committee slides (PDF 611 KB)

Draft guidance

Appraisal consultation document (PDF 381 KB)

Committee papers (PDF 8.56 MB)

Committee papers Presentation (PDF 729 KB)

Committee papers Presentation (PDF 797 KB)

Final scope (PDF 107 KB)

Final matrix (PDF 41 KB)

NICE's response to comments on the draft scope and provisional matrix (PDF 571 KB)

Equality impact assessment (Scoping) (PDF 66 KB)

Final protocol (PDF 450 KB)

Draft scope for consultation (pre-referral) certolizumab pegol - January 2015 (PDF 109 KB)

Provisional matrix (pre-referral) certolizumab pegol - January 2015 (PDF 47 KB)

Draft scope for consultation (pre-referral) secukinumab - January 2015 (PDF 108 KB)

Provisional matrix (pre-referral) secukinumab - January 2015 (PDF 46 KB)